SR biotek Statistics
Total Valuation
SR biotek has a market cap or net worth of KRW 26.32 billion.
| Market Cap | 26.32B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SR biotek has 1.66 million shares outstanding.
| Current Share Class | 1.66M |
| Shares Outstanding | 1.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.79% |
| Owned by Institutions (%) | 5.72% |
| Float | 417,037 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.25 |
| PB Ratio | 48.37 |
| P/TBV Ratio | 48.43 |
| P/FCF Ratio | 1,173.59 |
| P/OCF Ratio | 167.64 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 3.15.
| Current Ratio | 0.78 |
| Quick Ratio | 0.45 |
| Debt / Equity | 3.15 |
| Debt / EBITDA | 5.69 |
| Debt / FCF | 76.38 |
| Interest Coverage | 1.01 |
Financial Efficiency
Return on equity (ROE) is -13.21% and return on invested capital (ROIC) is 1.37%.
| Return on Equity (ROE) | -13.21% |
| Return on Assets (ROA) | 1.20% |
| Return on Invested Capital (ROIC) | 1.37% |
| Return on Capital Employed (ROCE) | 3.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.98 |
Taxes
In the past 12 months, SR biotek has paid 2.42 million in taxes.
| Income Tax | 2.42M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.74% in the last 52 weeks. The beta is 1.08, so SR biotek's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +2.74% |
| 50-Day Moving Average | 21,797.60 |
| 200-Day Moving Average | 23,493.15 |
| Relative Strength Index (RSI) | 33.18 |
| Average Volume (20 Days) | 744 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SR biotek had revenue of KRW 1.62 billion and -76.98 million in losses. Loss per share was -1,924.04.
| Revenue | 1.62B |
| Gross Profit | 744.58M |
| Operating Income | 51.55M |
| Pretax Income | -74.56M |
| Net Income | -76.98M |
| EBITDA | 300.90M |
| EBIT | 51.55M |
| Loss Per Share | -1,924.04 |
Balance Sheet
The company has 359.15 million in cash and 1.71 billion in debt, giving a net cash position of -1.35 billion or -817.79 per share.
| Cash & Cash Equivalents | 359.15M |
| Total Debt | 1.71B |
| Net Cash | -1.35B |
| Net Cash Per Share | -817.79 |
| Equity (Book Value) | 544.07M |
| Book Value Per Share | 13,599.45 |
| Working Capital | -188.60M |
Cash Flow
In the last 12 months, operating cash flow was 156.99 million and capital expenditures -134.56 million, giving a free cash flow of 22.43 million.
| Operating Cash Flow | 156.99M |
| Capital Expenditures | -134.56M |
| Free Cash Flow | 22.43M |
| FCF Per Share | 13.55 |
Margins
Gross margin is 45.96%, with operating and profit margins of 3.18% and -4.75%.
| Gross Margin | 45.96% |
| Operating Margin | 3.18% |
| Pretax Margin | -4.60% |
| Profit Margin | -4.75% |
| EBITDA Margin | 18.57% |
| EBIT Margin | 3.18% |
| FCF Margin | 1.38% |
Dividends & Yields
SR biotek does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -0.29% |
| FCF Yield | 0.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SR biotek has an Altman Z-Score of 0.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.8 |
| Piotroski F-Score | 3 |